Thrombotic thrombocytopenic purpura

Area of Science:

• Hematology
• Vascular Biology
• Thrombosis

Background:

• Congenital thrombotic thrombocytopenic purpura (cTTP) is characterized by platelet aggregation.
• Abnormalities in von Willebrand factor (vWF) multimers are implicated in cTTP pathogenesis.
• Elevated shear stress contributes to platelet aggregation in cTTP.

Purpose of the Study:

• To investigate the role of ultra-large von Willebrand factor (ULvWF) multimers in shear stress-induced platelet aggregation in cTTP patients.
• To determine the efficacy of plasma-derived products lacking large vWF multimers in reversing cTTP-related platelet aggregation.

Main Methods:

• Flow cytometry was used to assess vWF binding to platelets.
• Analysis of platelet aggregation under high shear stress conditions.
• Evaluation of therapeutic responses to plasma infusions (FFP, cryoprecipitate-poor plasma, cryosupernatant, solvent/detergent-treated plasma).

Main Results:

• cTTP patients exhibit excessive shear stress-induced platelet aggregation.
• The presence of ULvWF multimers in plasma correlates with increased vWF-binding to platelets.
• Infusion of plasma products devoid of large vWF multimers reversed platelet aggregation and cTTP relapses.

Conclusions:

• ULvWF multimers are likely responsible for inducing platelet aggregation in cTTP.
• These ULvWF multimers may originate from injured or abnormal endothelial cells.
• Targeting ULvWF multimers offers a potential therapeutic strategy for cTTP.